Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Allarity Therapeutics ( (ALLR) ) just unveiled an update.
On June 4, 2025, Allarity Therapeutics announced a research collaboration with the Indiana Biosciences Research Institute to enhance the understanding of stenoparib’s dual therapeutic mechanism. This collaboration aims to deepen the mechanistic understanding of stenoparib, a dual PARP and WNT pathway inhibitor, which could potentially improve Allarity’s clinical development strategy and support future marketing approval efforts. The research is expected to strengthen Allarity’s DRP®-based patient selection strategy and open new therapeutic opportunities, underscoring the company’s commitment to scientific excellence and personalized oncology.
Spark’s Take on ALLR Stock
According to Spark, TipRanks’ AI Analyst, ALLR is a Underperform.
Allarity Therapeutics’ overall stock score is low due to significant financial challenges, including no revenue and consistent operational losses. Technical analysis shows a bearish trend with neutral momentum indicators, while valuation metrics are unfavorable with a negative P/E ratio and no dividend yield. These factors collectively suggest a high-risk investment with limited current appeal.
To see Spark’s full report on ALLR stock, click here.
More about Allarity Therapeutics
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments. The company is dedicated to the development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, utilizing its proprietary Drug Response Predictor (DRP®) technology to create a companion diagnostic for patient selection. Allarity is headquartered in the U.S. with a research facility in Denmark, aiming to address significant unmet medical needs in cancer treatment.
Average Trading Volume: 1,427,457
Technical Sentiment Signal: Sell
Current Market Cap: $13.25M
Find detailed analytics on ALLR stock on TipRanks’ Stock Analysis page.